Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Better Risk Assessment And Dose Determination Key To EMA's Plans For Updated Phase I Trial Guideline

Executive Summary

Proposed revisions to the European Medicines Agency's guideline on first-in-human studies are intended to help identify and reduce the risks to study participants by making better use of non-clinical data in areas like the choice of the therapeutic dose, the dose escalation strategy, and the criteria for stopping a trial.

Advertisement

Related Content

Revised EMA Guideline On First-In-Human Trials Addresses Dosing And Complex Protocols
New French Clinical Trial Rules Focus on Phase I
EMA First-In-Human Trial Proposals Focus On Dosing, Non-Clinical Data, Study Design
EMA To Beef Up Use Of PBPK Models In Drug Development And Evaluation
Phase I Trials: French Body Urges Transparency, Says Don't Just Follow The Rules

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel